Advertisement Lutronic wins clearance for Spectra VRM III laser system - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Lutronic wins clearance for Spectra VRM III laser system

Lutronic has received the FDA clearance to market its Spectra VRM III, a dual pulse Q-switched Nd:yag laser, which produces four wavelengths of 1064nm, 532nm, 585nm, 650nm in Q-switched nanosecond pulse.

Lutronic’s Spectra VRM III is said to be specifically designed to treat a wide array of dermatological and aesthetic conditions, including dermal and epidermal pigmented lesions, multicolor tattoos, melasma, and active acne. It further enables laser toning, and non-ablative photo-acoustic skin rejuvenation techniques. The laser incorporates a dual pulse mode, which enables it to produce very short and quasi-long microsecond pulses.

Sooil Chun, clinical professor of Yonsei University, said: “The VRM III is extremely effective for the treatment of melasma. I have been achieving near 100% clearance on melasma treatment therapy. This is very impressive because melasma is traditionally thought to be treatment resistant. Further, the VRM has also been highly effective for the treatment of post-inflammatory hyperpigmentation that may result as adverse side affects from other lasers or intense pulsed light treatments.”